Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Hybrid Nanoplatforms for Theranostics Nanomedicine
share announcement

Hybrid Nanoplatforms for Theranostics Nanomedicine

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Biomedical Materials and Nanomedicine".

Deadline for manuscript submissions: closed (31 July 2021) | Viewed by 6730

Special Issue Editor

Dr. Nanasaheb Thorat

E-Mail Website
Guest Editor
Nuffield Department of Women’s & Reproductive Health, Medical Science Division, University of Oxford, Oxford, UK
Interests: cancer nanotechnology; hybrid nanostructures; antibacterial nanomedicine; drug delivery; tumor imaging; nanomedicine for infectious diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nanomedicine, the therapeutic branch of nanotechnology, has reached next generation clinical advances, and many nanomedicine products have been approved for cancer and infectious disease therapies. Hybrid nanoplatforms are capable of performing additional therapeutic modality in cancer and infectious disease management. The therapeutic modalities include early detection of the diseased cells, disease diagnosis, drug loading and delivery, external and internal stimuli responsive drug delivery, therapy, and therapy monitoring. A number of hybrid nanoplatforms have been developed to fight cancer and deadly pathogens; these hybrid nanoplatform include organic nanostructures, polymers, liposomes, lipids, inorganic nanostructures, gold nanoparticles, magnetic materials, silica nanoparticles, silver nanoparticles, titanium dioxide nanoparticles, biomolecules, protein, DNA nanostructures, antimicrobial peptides, metallic nanoparticles, and antiviral hybrid platforms.

Dr. Nanasaheb Thorat
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Organic nanostructures
  • Inorganic nanostructures
  • Hybrid organic–inorganic nanostructures
  • Biomolecules
  • Antimicrobial nanostructures
  • Nanotheranostics (diagnostics + theranostics)
  • Hybrid nanostructures for imaging
  • Therapy monitoring
  • magnetic hyperthermia
  • photodynamic and photothermal therapy
  • ultrasound therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 3718 KiB  
Article
Novel Coagulation Factor VIII Gene Therapy in a Mouse Model of Hemophilia A by Lipid-Coated Fe3O4 Nanoparticles
by Yung-Tsung Kao, Yen-Ting Chen, Hueng-Chuen Fan, Tung-Chou Tsai, Shin-Nan Cheng, Ping-Shan Lai, Jen-Kun Chen and Chuan-Mu Chen
Biomedicines 2021, 9(9), 1116; https://doi.org/10.3390/biomedicines9091116 - 30 Aug 2021
Cited by 5 | Viewed by 2831
Abstract
Hemophilia A is a bleeding disease caused by loss of coagulation factor VIII (FVIII) function. Although prophylactic FVIII infusion prevents abnormal bleeding, disability and joint damage in hemophilia patients are common. The cost of treatment is among the highest for a single disease, [...] Read more.
Hemophilia A is a bleeding disease caused by loss of coagulation factor VIII (FVIII) function. Although prophylactic FVIII infusion prevents abnormal bleeding, disability and joint damage in hemophilia patients are common. The cost of treatment is among the highest for a single disease, and the adverse effects of repeated infusion are still an issue that has not been addressed. In this study, we established a nonviral gene therapy strategy to treat FVIII knockout (FVIII KO) mice. A novel gene therapy approach was developed using dipalmitoylphosphatidylcholine formulated with iron oxide (DPPC-Fe3O4) to carry the B-domain-deleted (BDD)-FVIII plasmid, which was delivered into the FVIII KO mice via tail vein injection. Here, a liver-specific albumin promoter-driven BDD-FVIII plasmid was constructed, and the binding ability of circular DNA was confirmed to be more stable than that of linear DNA when combined with DPPC-Fe3O4 nanoparticles. The FVIII KO mice that received the DPPC-Fe3O4 plasmid complex were assessed by staining the ferric ion of DPPC-Fe3O4 nanoparticles with Prussian blue in liver tissue. The bleeding of the FVIII KO mice was improved in a few weeks, as shown by assessing the activated partial thromboplastin time (aPTT). Furthermore, no liver toxicity, thromboses, deaths, or persistent changes after nonviral gene therapy were found, as shown by serum liver indices and histopathology. The results suggest that this novel gene therapy can successfully improve hemostasis disorder in FVIII KO mice and might be a promising approach to treating hemophilia A patients in clinical settings. Full article
(This article belongs to the Special Issue Hybrid Nanoplatforms for Theranostics Nanomedicine)
►▼ Show Figures

Graphical abstract

12 pages, 3161 KiB  
Article
Self-Assembling β-Glucan Nanomedicine for the Delivery of siRNA
by Kyungwoo Lee, Daejin Min, Yonghyun Choi, Semi Yoon, Jaehee Jang, Jangsun Hwang, Hojeong Jeon, Yong Woo Cho and Jonghoon Choi
Biomedicines 2020, 8(11), 497; https://doi.org/10.3390/biomedicines8110497 - 12 Nov 2020
Cited by 7 | Viewed by 3400
Abstract
We aimed to design and manufacture a transporter capable of delivering small interfering RNAs (siRNAs) into the skin without causing any damage. β-glucans are unique chiral polysaccharides with well-defined immunological properties and supramolecular wrapping ability. However, the chiral properties of these polymers have [...] Read more.
We aimed to design and manufacture a transporter capable of delivering small interfering RNAs (siRNAs) into the skin without causing any damage. β-glucans are unique chiral polysaccharides with well-defined immunological properties and supramolecular wrapping ability. However, the chiral properties of these polymers have hardly been applied in drug delivery systems. In this study, β-glucan nanoparticles were designed and manufactured to deliver genetic material to the target cells. The β-glucan molecules were self-assembled with an siRNA into nanoparticles of 300–400 nm in diameter via a conformational transition process, in order to construct a gene delivery system. The assembled gene nanocarriers were associated with high gene-loading ability. The expression and efficiency of siRNA were verified after its delivery via β-glucan. Our results provide evidence that β-glucan nanoparticles can be effectively used to deliver siRNA into the cells. Full article
(This article belongs to the Special Issue Hybrid Nanoplatforms for Theranostics Nanomedicine)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop